Clinuvel Pharmaceuticals Ltd
ASX:CUV
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Price:
15.9 AUD
5.02%
Market Closed
Updated:
Jun 1, 2024
Clinuvel Pharmaceuticals Ltd
Capital Expenditures
|
Clinuvel Pharmaceuticals Ltd
Capital Expenditures Peer Comparison
Comparables:
IMM
MSB
CSL
TLX
PYC
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Capital Expenditures
-AU$5.9m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-89%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Capital Expenditures
-AU$82.7k
|
CAGR 3-Years
-109%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
17%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Capital Expenditures
-$281k
|
CAGR 3-Years
48%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Capital Expenditures
-$1.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-14%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Capital Expenditures
-AU$10.8m
|
CAGR 3-Years
-222%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Capital Expenditures
-AU$627.2k
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-317%
|
CAGR 10-Years
-7%
|
See Also
What is Clinuvel Pharmaceuticals Ltd's Capital Expenditures?
Capital Expenditures
-5.9m
AUD
-5.9m
AUD
Based on the financial report for Dec 31, 2023, Clinuvel Pharmaceuticals Ltd's Capital Expenditures amounts to -5.9m AUD.
What is Clinuvel Pharmaceuticals Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-89%
-89%
Over the last year, the Capital Expenditures growth was -668%. The average annual Capital Expenditures growth rates for Clinuvel Pharmaceuticals Ltd have been -59% over the past three years , -89% over the past five years .
You don't have any saved screeners yet
